Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Genenta Science S.p.A.

MILAN AND NEW YORK, JULY 01, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A PIONEER IN IMMUNO-ONCOLOGY, TODAY ANNOUNCED THAT A TOTAL OF 38 PATIENTS WERE ENROLLED IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (TEM-GBM) STUDY, WITH 25 PATIENTS RECEIVING TEMFERON. TWO PATIENTS HAVE BEEN ENROLLED IN THE TEM-LT LONG-TERM FOLLOW-UP STUDY, SURVIVING THREE YEARS FROM THE TIME OF 1STSURGERY.

GENENTA ANNOUNCES LONG-TERM FOLLOW-UP OBSERVATIONS IN BRAIN TUMOR (GBM) STUDY WITH EMERGING SURVIVAL SIGNALS

MILAN, ITALY AND NEW YORK, NEW YORK--(NEWSFILE CORP. - MAY 8, 2025) - GENENTA SCIENCE, SPA (NASDAQ: GNTA), TODAY ANNOUNCED ITS PARTICIPATION IN THE D. BORAL CAPITAL INAUGURAL GLOBAL CONFERENCE, TAKING PLACE MAY 14, 2025, AT THE PLAZA HOTEL IN NEW YORK CITY.

GENENTA SCIENCE, SPA ANNOUNCES PARTICIPATION IN THE D. BORAL CAPITAL INAUGURAL GLOBAL CONFERENCE

MILAN AND NEW YORK, MAY 07, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A PIONEER IN IMMUNO-ONCOLOGY AND A LEADER IN CELL-BASED THERAPEUTICS, TODAY ANNOUNCED A COLLABORATION WITH ANEMOCYTE, A LEADING BIOTECH MANUFACTURING ORGANIZATION (BMO) BASED IN ITALY. THIS STRATEGIC PARTNERSHIP MARKS A MAJOR MILESTONE, ENCOMPASSING THE SUCCESSFUL PRODUCTION OF CRITICAL STARTING MATERIALS, INCLUDING THE ESTABLISHMENT OF CELL BANKS AND THE MANUFACTURING OF PLASMIDS FOR VIRAL VECTOR PRODUCTION.

GENENTA AND ANEMOCYTE ANNOUNCE A COLLABORATION FOR THE MANUFACTURING OF STARTING MATERIALS FOR CUTTING-EDGE CELL-BASED THERAPIES

MILAN AND NEW YORK, APRIL 15, 2025 (GLOBE NEWSWIRE) -- PIERLUIGI PARACCHI, CEO GENENTA SCIENCE (NASDAQ: GNTA), A PIONEER IN IMMUNO-ONCOLOGY AND A LEADER IN CELL-BASED THERAPEUTICS, WILL PRESENT AT MONTALCINI GLOBAL BIOTECH TOUR IN DOHA, QATAR ON  APRIL 17TH, 2025AT THESHEIKH FAHAD BIN JASSIM AL THANI THEATRE, MINISTRY OF COMMERCE AND INDUSTRY (MOCI) BUILDING. FOLLOWING THE ANNOUNCEMENT OF A 20 MILLION ($22.7 MILLION) STRATEGIC FINANCING THROUGH THE ISSUANCE OF A MANDATORY CONVERTIBLE BOND TO ENEA TECH AND BIOMEDICAL (ETB)  AIMED AT EXPANDING GENENTA'S PIPELINE WITH THE ADVANCEMENT OF TEMFERON IN METASTATIC RENAL CELL CANCER (MRCC)  AND THE ADDITION OF APPROXIMATELY  3.0 MILLION ($3.2 MILLION) RAISED VIA AT-THE-MARKET (ATM) FACILITY, GENENTA CEO PIERLUIGI PARACCHI WILL PRESENT AT THE EVENT, WHICH WILL BE HOSTED BY H.E.

GENENTA SHOWCASES STRATEGIC VISION AT PREMIER BIOTECH FORUM IN QATAR

MILAN AND NEW YORK, MARCH 19, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A PIONEER IN IMMUNO-ONCOLOGY AND A LEADER IN CELL-BASED THERAPEUTICS, TODAY ANNOUNCED A 20 MILLION ($21.9 MILLION) FINANCING THROUGH THE ISSUANCE OF A MANDATORY CONVERTIBLE BOND TO ENEA TECH AND BIOMEDICAL (ETB) TO SUPPORT THE EXPANSION OF ITS PIPELINE BY ADVANCING TEMFERON IN METASTATIC RENAL CELL CANCER (MRCC). ETB IS A LEADING PRIVATE FOUNDATION, SUPERVISED BY THE ITALIAN MINISTRY OF ENTERPRISES AND MADE IN ITALY, MANAGING OVER 1,7 BILLION IN ASSETS UNDER MANAGEMENT THROUGH TWO FUNDS.

GENENTA ANNOUNCES 20 MILLION ($21.9M) FINANCING TO EXPAND PIPELINE AS BRAIN TUMOR TRIAL IS SHOWING PROMISING SURVIVAL RATES

OVER 230 ITALIAN AND U.S. EXECUTIVES, ITALIAN GOVERNMENT LEADERS, AND INVESTORS ATTENDED THE EIGHTH EDITION OF "ITALY ON THE MOVE" SEVEN LIFE SCIENCES EXECUTIVES PROVIDED BUSINESS INSIGHTS DURING "NAVIGATING TRANSATLANTIC PARTNERSHIPS IN LIFE SCIENCES" PANEL DISCUSSION AND FIVE ITALIAN STARTUPS PITCHED THEIR UNIQUE BREAKTHROUGHS AND INVESTMENT OPPORTUNITIES DIRECTOR GENERAL FOR THE PROMOTION OF ITALY MAURO BATTOCCHI DISCUSSED PRIVATE AND PUBLIC/INSTITUTIONAL FINANCIAL OPPORTUNITIES IN THE 270 BILLION ITALIAN LIFE SCIENCES SECTOR 1 SAN FRANCISCO , JAN. 28, 2025 /PRNEWSWIRE/ --THE ITALIAN TRADE AGENCY (ITA) COLLABORATED WITH THE MINISTRY OF FOREIGN AFFAIRS AND INTERNATIONAL COOPERATION TO HOST THE EIGHTH EDITION OF "ITALYON THE MOVE," A SIDE EVENT DURING THE 43RDANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 2025 AT INNOVIT - THE ITALIAN INNOVATION AND CULTURE HUB.

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

MILAN AND NEW YORK, JAN. 09, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A PIONEER IN IMMUNO-ONCOLOGY AND A LEADER IN CELL-BASED THERAPEUTICS, IS PLEASED TO ANNOUNCE THAT IT HAS STRENGTHENED ITS PARTNERSHIP WITH AGC BIOLOGICS, A GLOBAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO), BY AMENDING THEIR DEVELOPMENT AND MASTER SERVICES AGREEMENT. THIS AMENDMENT INTRODUCES AN EXCLUSIVE GMP SUITE AT THE AGC BIOLOGICS CELL AND GENE CENTER OF EXCELLENCE IN MILAN, DEDICATED TO THE MANUFACTURING OF GENENTA'S CELL THERAPY PRODUCT, ENSURING COMPLIANCE WITH CGMP STANDARDS.

GENENTA STRENGTHENS AGREEMENT WITH AGC BIOLOGICS TO BOOST CELL THERAPY MANUFACTURING

EVENT SHOWCASES ITALY AS LEADING COMPETITIVE HUB FOR INVESTMENTS IN BIOTECH, HEALTHCARE, MEDICAL DEVICES, AND PHARMACEUTICALS, AND INCLUDES EXPERTS DISCUSSING PRIVATE AND PUBLIC/INSTITUTIONAL FINANCIAL OPPORTUNITIES IN THE 270 BILLION ITALIAN LIFE SCIENCES SECTOR 1 SAN FRANCISCO , JAN. 8, 2025 /PRNEWSWIRE/ -- TO PROMOTE INVESTMENT OPPORTUNITIES IN ITALY IN 2025,THE ITALIAN TRADE AGENCY (ITA) AND THE MINISTRY OF FOREIGN AFFAIRS AND INTERNATIONAL COOPERATION WILL BE HOSTING THE EIGHTH EDITION OF "ITALY ON THE MOVE," A SIDE EVENT OF THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 2025.

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

GENENTA'S CEO TO PRESENT AT THE U.S. SENATE, WASHINGTON D.C.AT THE MEETING CROSS-BORDER INVESTMENTS AND STRATEGIES IN THE BIOTECHNOLOGY SECTOR: A TRANSATL

GENENTA'S CEO TO PRESENT AT THE U.S. SENATE MEETING ON CROSS-BORDER INVESTMENTS AND STRATEGIES IN THE BIOTECHNOLOGY SECTOR: A TRANSATLANTIC PERSPECTIVE

MILAN AND NEW YORK, OCT. 02, 2024 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A PIONEER IN IMMUNO-ONCOLOGY AND A LEADER IN CELL-BASED THERAPEUTICS, IS PLEASED TO ANNOUNCE THAT THE AGENZIA ITALIANA DEL FARMACO (AIFA) HAS APPROVED A NEW PHASE 1 CLINICAL TRIAL FOR METASTATIC RENAL CELL CANCER (MRCC), MARKING A SIGNIFICANT EXPANSION OF THE POTENTIAL APPLICATIONS FOR GENENTA'S FLAGSHIP PRODUCT, TEMFERON. THIS APPROVAL BY AIFA IS IN LINE WITH THE STANDARDS THAT ARE HARMONIZED ACROSS EUROPEAN REGULATORY FRAMEWORKS ESTABLISHED BY THE EUROPEAN MEDICINES AGENCY (EMA).

Genenta Science S.p.A.

GNTA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Genenta Science S.p.A.

GNTA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

GNTA